All In Biotech

Drug Trial Radar · NCT04531865

Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment

Efficacy and Safety of Mycophenolate Mofetil as Maintenance Therapy After Rituximab Treatment in Childhood-onset, Frequently-relapsing or Steroid-dependent Nephrotic Syndrome: a Multicenter Double-blind, Randomized, Placebo-controlled Trial

Last checked: Nov 19, 2026Latest source record: Dec 29, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

WithdrawnPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Withdrawn

Enrollment

0

Actual

Start

Jan 1, 2021

Primary completion

Sep 1, 2022

Study completion Oct 1, 2022

Sponsor

Lead sponsor
Children's Hospital of Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Children's Medical Center; Shanghai Children's Hospital
First posted
Aug 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate the efficacy and safety of maintenance Mycophenolate Mofetil following single course of Rituximab in maintaining remission over 12 months among Children with frequently-relapsing or steroid-dependent nephrotic syndrome

Conditions

  • Frequently Relapsing Nephrotic Syndrome
  • Steroid-Dependent Nephrotic Syndrome

Interventions

  • RituximabDrug

    Rituximab: 375 mg/m2 intravenously on day 0 and day 7

  • Mycophenolate MofetilDrug

    Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards. Dose: 20\~30mg/kg/day,BID. Total duration : 8 months.

  • Placebo tablets matching Mycophenolate MofetilDrug

    Addition of Maintenance Placebo tablets matching Mycophenolate Mofetil from 4 Month onwards. Dose: 20\~30mg/kg/day,BID. Total duration : 8 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1-year relapse-free survival rateTime frame: 1-year period after randomization

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Shanghai Children's Hospital

    Shanghai, China

  • Shanghai Children's Medical Center

    Shanghai, China

  • Xinhua Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, China

  • Children's hospital of Fudan university

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.